The AUGUSTUS trial (2 × 2 factorial design) demonstrated that in AF patients post-PCI, combining a P2Y12 inhibitor with a NOAC (without aspirin or VKA) reduced bleeding risk and cardiovascular hospitalization without increasing ischemic events [42]. The gene discussed is P2RY12; the disease is atrial fibrillation.